Trial Profile
EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis : A Double Blinded Randomized Clinical Trial
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 23 Nov 2023
Price :
$35
*
At a glance
- Drugs Infliximab (Primary) ; Vedolizumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms EFFICACI
- 08 Nov 2022 Planned End Date changed from 4 Jan 2024 to 4 Jan 2025.
- 08 Nov 2022 Planned primary completion date changed from 4 Jan 2023 to 4 Jan 2024.
- 05 Jan 2021 Planned End Date changed from 4 Jan 2022 to 4 Jan 2024.